Genscript Biotech valuation
$27.76Change from previous close: −7.96%Absolute change: −$2.40
Valuation
The average price target of 6 analysts is $45.43.
Data as of November 21, 2026
Genscript Biotech compared with similar companies
Genscript Biotech's Forward P/E: 76.9, +142% against the median of a group of 10 similar companies (31.7).
| Metric | Genscript Biotech | Median | 25th–75th percentile | Band |
|---|---|---|---|---|
| Forward P/E | 76.9 | 31.7 | 20.4 – 43.6 | High |
| EV/EBITDA | 340.0 | 37.9 | 18.2 – 67.6 | High |
| Price/book | 2.16 | 5.24 | 2.69 – 8.16 | Low |
| Price/sales | 81.4 | 8.89 | 4.67 – 31.6 | High |
| Gross margin | 52.0% | 74.6% | 49.8% – 79.1% | Middle |
| Operating margin | 14.9% | 14.9% | 6.8% – 30.3% | Middle |
| Net margin | -75.4% | 7.8% | 5.4% – 21.4% | Low |
| ROE | -15.3% | 10.4% | 5.0% – 19.8% | Low |
| Debt/equity | 0.09 | 0.11 | 0.05 – 0.40 | Middle |
Group: the stock and up to 10 companies in the same industry (with fewer than 5, related industries too), same region first, with a similar size. Band: low = the lowest quarter of values in the group, middle = 25th to 75th percentile, high = the highest quarter. Negative multiples and multiples above 500 are excluded; a comparison needs at least 5 values. The group is recalculated nightly.
TickerLandia analysisHow it is calculated
Companies in the group: same industry, similar size
Other metrics
Valuation multiples
- Market cap
- $68.78B
- Enterprise value
- $65.49B
- P/E (trailing 12 months)
- -13.0
- EV/revenue
- 77.5
Profitability and growth
- ROA
- 1.5%
- ROIC
- 1.7%
- Revenue growth (year over year)
- -22.1%
- Earnings growth (year over year)
- 174.4%
Financial health
- Total cash
- $810.27M
- Total debt
- $343.53M
- Current ratio
- 1.53
- Quick ratio
- 1.33
- Altman Z-Score
- 3.58
- Piotroski F-Score
- 4.00
Dividends
- Payout ratio
- 0.0%
- Ex-dividend date
- June 5, 2017
Analysts and estimates
- Average price target
- $45.43
- Median price target
- $38.53
- High price target
- $87.95
- Low price target
- $29.99
- Analysts with a price target
- 6
- Forward EPS
- $0.39
- EPS estimate, current year
- $0.03
Shares and trading
- Beta
- 0.92
- Average volume
- 42.3M
- Shares outstanding
- 2.28B
- Float
- 1.41B
- Institutional ownership
- 29.0%
- Insider ownership
- 35.2%
